TCGA-CV-7235-01A-11R-2016-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.590
- TNFA_SIGNALING_VIA_NFKB+0.540
- INTERFERON_GAMMA_RESPONSE+0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.480
- ALLOGRAFT_REJECTION+0.440
- ANGIOGENESIS+0.440
- HYPOXIA+0.390
- HEDGEHOG_SIGNALING+0.380
- INFLAMMATORY_RESPONSE+0.350
- IL6_JAK_STAT3_SIGNALING+0.330
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.400
- PROTEIN_SECRETION-0.360
- FATTY_ACID_METABOLISM-0.340
- DNA_REPAIR-0.280
- E2F_TARGETS-0.270
- BILE_ACID_METABOLISM-0.250
- PANCREAS_BETA_CELLS-0.250
- PEROXISOME-0.180
- MITOTIC_SPINDLE-0.160
- XENOBIOTIC_METABOLISM-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CN-5370-01A-01R-2016-07 | — | — | 0.842 |
| 2 | BS_06AMMCXR | low-grade glioma | — | 0.839 |
| 3 | BS_G1Y281HX | Neuroblastoma | — | 0.837 |
| 4 | TCGA-56-8503-01A-11R-2403-07 | — | cohortSQ1 | 0.837 |
| 5 | SRR6013602 | — | cohortMD2 | 0.834 |
| 6 | AUR-AER2-TTM3-A-1-1-R-A742-41 | — | D | 0.833 |
| 7 | BS_GDHH6T5A | Neurofibroma | — | 0.827 |
| 8 | ERR2278883 | — | — | 0.826 |
| 9 | C3L-02170 | — | cohortMD2 | 0.825 |
| 10 | BS_X91K8KMG | pilocytic astrocytoma | — | 0.824 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.590 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.540 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.520 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.480 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.440 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.440 | Remibrutinib | — uncovered |
| HYPOXIA | 0.390 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.380 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.350 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.330 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.310 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.310 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.290 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.250 | Inavolisib | — uncovered |
| APOPTOSIS | 0.250 | Idelalisib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| COAGULATION | 0.230 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.210 | Temsirolimus | — uncovered |